智通财经APP讯，微创心通-B(02160)公布，董事会建议将公司股本按每5股每股面值0.000005美元的已 发行及未发行现有股份合并为1股每股面值0.000025美元的合并股份的基准实施股份合并。 于本公告日期，现有股份以每手买卖单位1,000股现有股份于联交所买卖。于股份合并生效后，于联交 所买卖的每手买卖单位将维持不变为1,000股合并股份。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或 因依賴該等內容而引致的任何損失承擔任何責任。 MicroPort CardioFlow Medtech Corporation 微創心通醫療科技有限公司 一般事項 股份合併須待（其中包括）股東於股東特別大會上以投票表決方式投票通過 普通決議案及上市委員會批准合併股份上市及買賣後，方可作實。概無股 東參與股份合併或於其中擁有權益或重大權益，因此概無股東須於股東特 別大會上放棄以投票表決方式投票通過決議案以批准股份合併。 本公司將召開及舉行股東特別大會以供股東考慮並酌情批准股份合併。一 份載有（其中包括）有關股份合併進一步詳情及召開股東特別大會通告之通 函預期將於2026年1月27日（星期二）或之前寄發予股東。 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：2160） 建議股份合併 董事會建議將本公司股本按每五(5)股每股面值0.000005美元的已發行及未發 行現有股份合併為一(1)股每股面值0.000025美元的合併股 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或 因依賴該等內容而引致的任何損失承擔任何責任。 MicroPort CardioFlow Medtech Corporation 為確定股東出席股東特別大會並於會上投票的資格，本公司將於2026年2月6日 （星期五）至2026年2月11日（星期三）（包括首尾兩日）期間暫停辦理股份過戶登 記，期間不會辦理任何股份過戶登記手續。為確定有權出席股東特別大會並於 會上投票的股東的身份，所有過戶文件連同有關股票須於2026年2月5日（星期 四）下午四時三十分前交回本公司的香港股份過戶登記分處香港中央證券登記 有限公司，地址為香港灣仔皇后大道東183號合和中心17M樓，以作登記。 承董事會命 微創心通醫療科技有限公司 主席 陳國明 香港，2026年1月22日 截至本公告日期，執行董事為張瑞年先生及Philippe Wanstok先生；非執行董事為陳國明先生、 Brian Chang博士、鄧奧弋先生及吳夏女士；及獨立非執行董事為周嘉鴻先生、孫志祥女士及 胡冰山博士 ...

香港联交所最新资料显示，1月21日，微创心通-B(02160)股东将股票存入云锋证券，存仓市值6.51亿港 元，占比9.56%。 微创心通公告，由集团联营公司4C Medical Technologies, Inc.(4C Medical)自主研发的AltaValveTM经导 管二尖瓣置换(TMVR)医疗器械(AltaValveTM)的早期可行性研究一年随访结果正式公布。本次研究覆盖 欧洲、美国、日本多中心，纳入患者30名，均为手术高风险、伴有症状性重度二尖瓣反流(MR)的患 者，其中13名患者采用经心尖入路， 17名采用经房间隔入路。 ...

微创心通公告，由集团联营公司4C Medical Technologies, Inc.(4C Medical)自主研发的AltaValveTM经导 管二尖瓣置换(TMVR)医疗器械(AltaValveTM)的早期可行性研究一年随访结果正式公布。本次研究覆盖 欧洲、美国、日本多中心，纳入患者30名，均为手术高风险、伴有症状性重度二尖瓣反流(MR)的患 者，其中13名患者采用经心尖入路， 17名采用经房间隔入路。 智通财经APP获悉，香港联交所最新资料显示，1月21日，微创心通-B(02160)股东将股票存入云锋证 券，存仓市值6.51亿港元，占比9.56%。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 微创心通医疗科技有限公司 呈交日期: 2026年1月7日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02160 | 說明 | 普通股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | USD | 0.000005 | USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 10,000,000,000 | USD | | 0.000005 USD | | 50,000 | 本月底法定/註冊股本總額： U ...

Financing Overview - In the week from December 29 to January 4, Shanghai saw a total of 30 financing events, with 17 disclosing their amounts, totaling 3.658 billion yuan, which is an increase of 14 events compared to the previous week [4] - The highest number of financing events occurred in Pudong New District with 8 events, followed by Yangpu District and Jiading District with 4 events each [4] - A significant financing event in the integrated circuit sector was reported in Changning, amounting to 2.57 billion yuan [4] Company Dynamics - New Micro Group completed a strategic financing round of 2.57 billion yuan on December 30, with investments from multiple funds including the National Green Development Fund and Shanghai International Group [13] - Dongsheng Fusion secured several hundred million yuan in angel round financing on January 4, backed by prominent investors such as IDG Capital and Sequoia China [15] - Borui Biotech completed over 100 million yuan in A-round financing on December 29, led by Qianji Capital [17] - Chenxin Technology received a strategic financing round of over 100 million yuan on December 31, with investments from Changjiang Innovation and Jinpu Intelligent [19] Industry Focus - The healthcare sector had 7 financing events this week, focusing on pharmaceuticals and medical devices [21] - Microinvasive Heart's VitaFlow Liberty® system received approval for market entry in Morocco on December 29, while Qilu Pharmaceutical's global R&D headquarters project commenced in Zhangjiang [21] - The Shanghai government aims to enhance the international competitiveness of local biopharmaceutical companies, targeting over 50 billion yuan in exports and 2-3 companies achieving over 10 billion yuan in overseas sales by 2027 [21]

Group 1 - The stock of MicroPort Scientific Corporation-B (02160.HK) experienced a significant increase, rising over 10% at one point and currently up by 8.7%, trading at HKD 1.25 [1] - The trading volume reached HKD 11.4828 million, indicating strong market interest [1]

Core Viewpoint - MicroPort CardioFlow-B (02160) has seen a significant stock increase of over 10%, currently trading at 1.25 HKD with a transaction volume of 11.48 million HKD, driven by positive developments in its product offerings and strategic mergers [1] Group 1: Product Development - The VitaFow series transcatheter aortic valves and delivery systems have been introduced in 35 countries and regions globally, with nearly 1,300 implants to date [1] - The projected implant volume for 2025 is expected to exceed 850 cases, representing a nearly 350% increase compared to 2024 [1] - The second half of 2025 is anticipated to see over 170% growth in implant volume compared to the first half [1] Group 2: Strategic Mergers - On December 21, the company announced a strategic merger with MicroPort Cardiac Rhythm Management, which is expected to enhance its resilience against risks by diversifying beyond a single focus on structural heart disease [1] - The merger will provide access to a more mature global sales network, facilitating accelerated expansion into overseas markets [1] - The collaboration aims to leverage both companies' research and development capabilities in medical devices to create a global platform for heart failure treatment [1]

Core Viewpoint - MicroPort CardioFlow-B (02160) has seen a significant stock increase, with a rise of over 10% and a current price of 1.25 HKD, reflecting strong market interest and positive developments in the company's product offerings [1] Group 1: Product Development and Market Expansion - The VitaFow series transcatheter aortic valves and delivery systems have been introduced in 35 countries, with nearly 1,300 implants to date [1] - The projected implant volume for 2025 is expected to exceed 850 cases, representing a nearly 350% increase compared to 2024 [1] - The second half of 2025 is anticipated to see over 170% growth in implant volume compared to the first half [1] Group 2: Strategic Developments - On December 21, the company announced a strategic merger with MicroPort Cardiac Rhythm Management, which is expected to enhance the company's resilience against risks by diversifying beyond a single market segment [1] - The merger will provide access to a more mature global sales network, facilitating accelerated expansion into overseas markets [1] - The collaboration aims to leverage both companies' research and development capabilities in medical devices to create a global platform for heart failure treatment [1]